Trends in 12-Month Mortality and Statutory Health Insurance Costs in Incident Metastatic Bladder Cancer in Germany, 2011–2024
In incident metastatic bladder cancer in Germany, costs per patient rose from €32,245 to €43,042 between 2011 and 2024, without any improvement in 12-month survival.
Rising Drug Costs With Stable 12-Month Survival in Incident Metastatic Breast Cancer in Germany, 2011–2024
In incident metastatic breast cancer in Germany, 12-month survival remained broadly stable from 2011 to 2024, while costs rose by 22.9%, driven by outpatient drugs.
Trends in 12-Month Mortality and Healthcare Costs in Incident Metastatic Colorectal Cancer in Germany, 2011–2024
In incident metastatic colorectal cancer in Germany, costs rose moderately (+17.2%) between 2011 and 2024 without a consistent improvement in 12-month survival.
Increasing Costs and Limited Mortality Improvement in Incident Metastatic Lung Cancer in German Statutory Health Insurance Claims, 2011–2024
Costs for incident metastatic lung cancer in Germany rose by 87.5% between 2011 and 2024, while 12-month survival improved only modestly and inconsistently.
More Than Doubling of Costs With Unchanged 12-Month Mortality in Incident Metastatic Prostate Cancer in Germany, 2011–2024
Costs per patient with incident metastatic prostate cancer in Germany more than doubled between 2011 and 2024 – while 12-month survival remained nearly unchanged.
Trends in Epidemiology and Mortality of Patients with Bladder Cancer in Germany: A Retrospective Study Using German Claims Data
Despite progress in the detection and treatment of bladder cancer (BC), it remains one of the common cancer diagnoses. Updated estimates of its epidemiology and mortality are needed to better understand the BC burden in Germany. This research aims to estimate the incidence/prevalence of BC in Germany and to describe trends in mortality in the last eleven years.
Monitoring the Burden of Lung Cancer in Germany: Trends in Incidence and Survival Using ZfKD Registry Data (2020–2023)
OBJECTIVES: To describe recent trends in lung cancer incidence, staging, morphology, and survival outcomes in Germany using comprehensive population-based data from the German Centre for Cancer Registry Data (ZfKD).
METHODS: This retrospective analysis included all lung cancer cases diagnosed from 2020 to 2023 in individuals aged 18 years or older. Anonymized data were sourced from the ZfKD, which compiles mandatory cancer notifications across the German federal states. Variables analyzed included patient demographics, tumor characteristics (histological subtype, stage), and Kaplan-Meier-based survival estimates stratified by cancer subtype and stage.
RESULTS: A total of 222,366 lung cancer cases were recorded, with incidence per 100 adults of 0.081, 0.082, 0.081, and 0.077 in 2020, 2021, 2022, and 2023, respectively. Non-small cell lung cancer (NSCLC) accounted for 82.6% of cases, while small cell lung cancer (SCLC) made up 13.8%. NSCLC patients were older at diagnosis than those with SCLC (mean 70.2 vs. 68.5 years). Stage IV was the most common at diagnosis (41% in NSCLC, 59% in SCLC). Median survival was 12.8 months for NSCLC and 8.1 months for SCLC, dropping to 6.5 and 6.8 months, respectively, in stage IV disease. Adenocarcinoma was the most frequent NSCLC subtype (40.5%), followed by squamous cell carcinoma (15.7%).
CONCLUSION: Late-stage lung cancer diagnosis remains common and contributes to poor short-term survival. These findings underscore the need for earlier detection strategies and continued research into treatment pathways and outcomes.
Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
Systematic literature review to identify real-world studies reporting NST or attrition rates in la/mUC from 2017–2022 (including data reported since 2015). Of 2439 publications screened, 29 reported NST rates, ranging from 40–74% in eight European-based studies, 14–60% in 12 US-based studies, and 9–63% in nine studies in other locations (meta-analysis estimate, 39%). Factors associated with NST or no second-line therapy included older age, female sex, poor performance status, poor renal function and distant metastases.
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.